Welcome to our dedicated page for Curevac B.V. news (Ticker: CVAC), a resource for investors and traders seeking the latest updates and insights on Curevac B.V. stock.
CureVac N.V. develops messenger RNA medicines for human medicine, with programs spanning cancer immunotherapy, prophylactic vaccines, and therapies designed to enable the body to produce therapeutic proteins. The company applies mRNA technology with omics and computational tools to off-the-shelf and personalized precision immunotherapy candidates, including oncology programs such as CVHNLC for squamous non-small cell lung cancer and CVGBM for glioblastoma.
CureVac news commonly covers operating and financial results, clinical and regulatory disclosures, patent litigation involving mRNA technologies such as split poly-A tail technology, and shareholder meeting outcomes. Updates also address governance votes, board and auditor matters, material agreements, capital-structure disclosures, and other corporate-status developments.
CureVac (NASDAQ:CVAC) has been notified by the German Federal Ministry of Education and Research of an expected funding of up to 252 million euros to support the development of its COVID-19 vaccine candidate, CVnCoV. This funding will aid in accelerating research and expanding production capacity. The grant will provide 103 million euros in 2020 and 149 million euros in 2021, contingent on meeting milestones. CEO Franz-Werner Haas emphasized the importance of this financial support to develop a safe and effective vaccine quickly.